What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
AbCellera
Discovers and develops antibody therapeutics using high throughput microfluidics.
What they do
AbCellera partners with pharmaceutical companies to search and analyze natural immune systems for potential antibody therapies. Their technology combines microfluidics, genomics, and machine learning to rapidly identify drug candidates for diverse therapeutic areas.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Antibody discovery
- Product type
- Service
- Stage
- Public
- Headquarters
- Vancouver, Canada
- Region
- North America
- Founded
- 2012
- Total funding
- $245M raised
Notable investors: Viking Global Investors, Peter Thiel, OrbiMed, DCVC.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
The Lawsuit Alleging an Algorithm, Not a Doctor, Decided When Grandma's Care Ended
The Lawsuit Alleging an Algorithm, Not a Doctor, Decided When Grandma's Care Ended
Dr. Dereck Mush, MD, MBA